Wegovy Cost Without Insurance 2026: $499-$1,400/Month + Cash-Pay Options
What Wegovy actually costs cash-pay in 2026: NovoCare, savings cards, retail pharmacy pricing, plus how the compounded semaglutide pathway is regulated differently.
Quick Answer: Wegovy Cash-Pay Pricing 2026
- Retail pharmacy: ~$1,200-$1,400/month without insurance
- NovoCare (self-pay program): ~$499/month for single-dose vials
- Wegovy Savings Card: Variable, eligibility-dependent
- Compounded semaglutide: a separate cash-pay pathway, prepared per individual prescription and not FDA-approved as a drug
Annual cash-pay cost for Wegovy: roughly $5,988/year through NovoCare and $14,400-$16,800/year at retail pharmacy pricing, depending on which program you qualify for.
About this guide
Pricing data based on publicly listed retail pharmacy prices, Novo Nordisk's published NovoCare and Wegovy Savings Card terms, and compounded telehealth provider rates as of May 2026. All prices subject to change. Wegovy is a registered trademark of Novo Nordisk. Trimi is an unaffiliated telehealth provider offering compounded semaglutide. This article is informational and not medical advice.
More on Brand-Name vs Compounded GLP-1 Cost
Wegovy Pricing Tiers (2026)
Novo Nordisk offers Wegovy through multiple price tiers depending on your insurance status and which program you qualify for:
| Pricing Path | Monthly Cost | Annual Cost | Eligibility |
|---|---|---|---|
| Retail pharmacy (CVS, Walgreens, etc.) | ~$1,200-$1,400/mo | $14,400-$16,800/yr | No restrictions; any patient with prescription |
| NovoCare (self-pay vials) | ~$499/mo | $5,988/yr | Self-pay patients via novocare.com |
| Wegovy Savings Card (with insurance) | Variable (~$25-$650/mo) | $300-$7,800/yr | Commercial insurance, eligibility checks apply |
Note: All Novo Nordisk programs subject to eligibility checks, supply, and program changes. Verify current pricing at novocare.com or wegovy.com before committing.
NovoCare: The Self-Pay Option
In response to compounded semaglutide gaining market share, Novo Nordisk launched NovoCare, a direct-to-patient program offering Wegovy at ~$499/month for self-pay patients (vs $1,200-$1,400 retail). Notably, NovoCare offers single-dose vials (not pens), which is similar to how compounded semaglutide is typically dispensed.
NovoCare specifics:
- Available via novocare.com, Novo Nordisk's direct platform
- Self-pay only (insurance bypassed for this program tier)
- ~$499/month for single-dose vials (standard doses)
- Pen delivery system priced separately and significantly higher
- Subject to availability and program terms, Novo Nordisk can adjust pricing
Annual cost via NovoCare: $5,988/year, compared with $14,400-$16,800/year at retail pharmacy pricing for the same brand-name product.
Why Cash-Pay Wegovy Costs $1,200+/Month
Brand-name Wegovy's high retail price reflects several factors:
- R&D recovery: Novo Nordisk invested billions in semaglutide development, clinical trials, and FDA approval. Brand pricing recovers those costs over the patent period.
- Manufacturing: Semaglutide is produced in FDA-approved facilities with strict quality controls, validated processes, and batch release testing, all of which carry ongoing cost.
- Marketing: Direct-to-consumer advertising, healthcare provider education, and sales force expenses are substantial.
- Insurance dynamics: Brand pricing factors in expected insurance rebates and manufacturer discounts that don't reach cash-pay patients. Cash-pay patients essentially subsidize the insured market.
- Supply constraints: Semaglutide has been on FDA's drug shortage list. Constrained supply gives Novo Nordisk pricing power for the limited brand-name product.
Compounded Semaglutide: A Separate Cash-Pay Pathway
For patients without insurance who don't qualify for Novo Nordisk's savings programs, compounded semaglutide is a separate cash-pay pathway with its own regulatory framework. Trimi's compounded semaglutide is $99/month flat.
What the Trimi pathway includes:
- $99/month flat on the annual plan, billed as a cash-pay subscription
- No membership fee and no separate shipping fee
- Ships free overnight once the prescription is compounded
- Prepared per individual prescription by a licensed 503A pharmacy
- Not FDA-approved as a drug, and not a generic version of Wegovy
The two pathways are regulated differently: brand-name Wegovy goes through FDA drug approval, while compounded semaglutide is prepared per individual prescription by licensed 503A/503B pharmacies under federal and state pharmacy oversight and is not FDA-approved as a drug.
Wegovy vs Ozempic: The Same-Drug Problem
Wegovy and Ozempic both contain semaglutide, made by Novo Nordisk. The only difference is FDA approval pathway: Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. Some patients who can't get Wegovy approved by insurance get Ozempic prescribed off-label for weight loss (especially patients who also have diabetes or pre-diabetes).
For cash-pay patients, both Wegovy and Ozempic cost approximately the same retail. The savings card programs differ slightly between the two. Compounded semaglutide sits outside both programs, since it is dispensed per individual prescription rather than as an FDA-approved product.
When Brand-Name Wegovy Is the Right Choice
Wegovy is the right pick if:
- Your insurance covers Wegovy and the copay is $50/month or less
- You qualify for the Wegovy Savings Card and the resulting out-of-pocket cost works for your budget
- You specifically want the FDA-approved brand-name product with full prescribing information for weight management
- You prefer the pen delivery system over single-dose vials (compounded semaglutide is typically dispensed in vials)
Frequently Asked Questions
How much does Wegovy cost without insurance in 2026?
Without insurance, Wegovy costs approximately $1,200-$1,400/month at retail pharmacies in 2026. Novo Nordisk's NovoCare direct-to-patient program offers Wegovy at ~$499/month for self-pay patients (single-dose vials). The Wegovy Savings Card may further reduce cost for eligible commercially insured patients without coverage, though eligibility caps apply.
What is NovoCare Wegovy pricing?
NovoCare is Novo Nordisk's direct-to-patient program offering Wegovy at ~$499/month for self-pay patients via single-dose vials (vs $1,200-$1,400 retail pen pricing). Available through NovoCare's website with eligibility requirements. Prices and program terms can change, verify current pricing on NovoCare.com before committing.
Can I use the Wegovy Savings Card without insurance?
The standard Wegovy Savings Card primarily reduces cost for commercially insured patients. Self-pay patients have separate program tiers via NovoCare with different pricing. Eligibility is checked by Novo Nordisk's program, apply at wegovy.com to see your specific cost.
How is compounded semaglutide different from Wegovy?
They follow different regulatory pathways. Wegovy is Novo Nordisk's FDA-approved product with an approved label and full prescribing information. Compounded semaglutide is prepared per individual prescription by licensed 503A/503B pharmacies, has not been evaluated by the FDA for safety, effectiveness, or quality, and is not FDA-approved as a drug. Trimi offers compounded semaglutide at $99/month flat as a cash-pay subscription.
Why is Wegovy so expensive without insurance?
Brand-name pharmaceutical pricing reflects R&D costs, manufacturing in FDA-approved facilities, marketing investment, and what the U.S. healthcare market will bear. Novo Nordisk recovered semaglutide development costs while the molecule is on patent. Brand pricing also factors in expected insurance rebates and manufacturer discounts that don't reach cash-pay patients at retail.
What are the legitimate alternatives to Wegovy?
Compounded semaglutide from licensed telehealth providers is the main alternative pathway. Trimi is $99/month flat (no membership fee, no shipping fee), while other compounded providers range $129-$329/month. Compounded preparations are made per individual prescription and are not FDA-approved as drugs.
What is known about compounded semaglutide's effectiveness?
Brand-name Wegovy has the advantage of pharmacokinetic studies, uniform manufacturing, and FDA approval. Compounded preparations have not been studied in clinical trials of their own and are not FDA-approved as drugs. Licensed 503A/503B pharmacies apply their own quality controls, which vary by pharmacy, so ask which one fills your prescription.
Disclaimer: Wegovy is a registered trademark of Novo Nordisk. NovoCare and Wegovy Savings Card are programs of Novo Nordisk with eligibility requirements and program terms that may change. Pricing is current as of May 2026 and subject to change. This article is informational and not medical advice. Always consult a licensed clinician about whether semaglutide (brand-name or compounded) is appropriate for your individual health situation.